SCHEMBL6489130

SCHEMBL6489130

CCOC(=O)c1ccc(-c2cc(C)c3nc(C)n(Cc4ccc(OCC)cc4Cl)c3c2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.40
TP53 P04637 1/20 0.40
DCTPP1 Q9H773 2/20 0.40
PDGFRB P09619 1/20 0.39
PDGFRA P16234 1/20 0.39
TSPO P30536 1/20 0.37
CHRNA7 P36544 3/20 0.37
KCNH2 Q12809 1/20 0.37
HRH3 Q9Y5N1 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36
PPARG P37231 1/20 0.36
SIRT2 Q8IXJ6 1/20 0.36
SIRT1 Q96EB6 1/20 0.36
SIRT3 Q9NTG7 1/20 0.36
ALDH1A1 P00352 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
NPC1 O15118 1/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6488456 0.92 DCTPP1 (0.44) DCTPP1TSPOCHRNA7PPARG
SCHEMBL6488896 0.90 DCTPP1 (0.40) MAPTTP53DCTPP1NPSR1PPARG
SCHEMBL6487673 0.88 JMJD6 (0.41) MAPTTP53DCTPP1NPSR1SMN1; SMN2
SCHEMBL6490611 0.84 ERN1 (0.37) MAPTTP53DCTPP1TSPOALDH1A1
SCHEMBL6490742 0.84 CYP1A2 (0.38) MAPTDCTPP1TSPOALDH1A1TDP1
SCHEMBL6488966 0.84 RXRA (0.41) TP53DCTPP1PPARGSMN1; SMN2NPC1
SCHEMBL6491045 0.84 DCTPP1 (0.42) MAPTDCTPP1TSPOCHRNA7PPARG
SCHEMBL6490173 0.83 RARB (0.47) TP53DCTPP1PPARGTSHR
SCHEMBL6488103 0.83 P4HTM (0.40) MAPTDCTPP1TSPOCHRNA7PPARG
SCHEMBL6490261 0.83 CYP1A2 (0.42) SIRT2SIRT1SMN1; SMN2RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed
WO-2004108686-A2 BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD MAPT 3168/4885TP53 1741/4885DCTPP1 1534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.